XENE · Xenon Pharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $88.51M | - | $77.05M | $74.98M | $61.20M | - | $56.97M | $49.70M | $44.25M | - |
| SG&A | $23.82M | - | $19.28M | $19.24M | $19.04M | - | $16.71M | $19.40M | $14.79M | - |
| Total Operating Expenses | $112.33M | - | $96.34M | $94.23M | $80.24M | - | $73.68M | $69.10M | $59.04M | - |
| D&A | $587.0K | - | - | - | $659.0K | - | - | - | $599.0K | - |
| Operating Income | ($112.33M) | - | ($96.34M) | ($94.23M) | ($72.74M) | - | ($73.68M) | ($69.10M) | ($59.04M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($2.57M) | - | $677.0K | ($626.0K) | $427.0K | - | ($320.0K) | ($333.0K) | $412.0K | - |
| Net Income | ($102.30M) | - | ($90.90M) | ($84.71M) | ($65.05M) | - | ($62.79M) | ($57.92M) | ($47.93M) | - |
| EPS - Basic | ($1.17) | - | ($1.15) | ($1.07) | ($0.83) | - | ($0.81) | ($0.75) | ($0.62) | - |
| EPS - Diluted | ($1.17) | - | ($1.15) | ($1.07) | ($0.83) | - | ($0.81) | ($0.75) | ($0.62) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $545.87M | $199.16M | $104.51M | $135.38M | $116.66M | $142.71M | $87.62M | $136.73M | $58.90M | $148.64M |
| Accounts Receivable | - | - | - | - | - | $1.47M | $938.0K | $853.0K | $833.0K | $874.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.75M | $3.88M | $4.55M | $4.79M | $6.88M | $5.07M | $5.42M | $9.50M | $6.43M | $8.60M |
| Current Assets | $1.11B | $560.65M | $480.14M | $500.25M | $565.54M | $635.26M | $659.64M | $728.09M | $707.20M | $644.96M |
| Total Assets | $1.39B | $633.16M | $607.84M | $674.28M | $743.28M | $798.14M | $835.90M | $884.01M | $919.02M | $964.80M |
| Current Liabilities | $39.81M | $41.79M | $38.34M | $33.05M | $32.03M | $35.59M | $29.70M | $31.29M | $22.22M | $27.27M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $48.99M | $51.40M | $48.33M | $40.30M | $39.32M | $43.24M | $38.09M | $39.96M | $31.32M | $36.88M |
| Stockholders' Equity | $1.34B | $581.76M | $559.51M | $633.98M | $703.96M | $754.90M | $797.81M | $844.05M | $887.70M | $927.92M |
| Retained Earnings | ($1.35B) | ($1.25B) | ($1.14B) | ($1.05B) | ($964.52M) | ($899.47M) | ($833.78M) | ($771.00M) | ($713.07M) | ($665.14M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($88.90M) | - | - | - | ($61.65M) | - | - | - | ($43.18M) | - |
| Investing Cash Flow | ($407.28M) | - | - | - | $34.51M | - | - | - | ($46.20M) | - |
| Financing Cash Flow | $843.01M | - | - | - | $0 | - | - | - | - | - |
| CapEx | $133.0K | - | - | - | $43.0K | - | - | - | $188.0K | - |
| Free Cash Flow | ($89.03M) | - | - | - | ($61.70M) | - | - | - | ($43.37M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.87 | - | - | - | 0.95 | - | - | - | 0.90 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.4% | - | -15.0% | -12.6% | -8.8% | - | -7.5% | -6.6% | -5.2% | - |
| Return on equity | -7.6% | - | -16.2% | -13.4% | -9.2% | - | -7.9% | -6.9% | -5.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 27.79 | 13.42 | 12.52 | 15.14 | 17.66 | 17.85 | 22.21 | 23.27 | 31.82 | 23.65 |
| Quick ratio | 27.79 | 13.42 | 12.52 | 15.14 | 17.66 | 17.85 | 22.21 | 23.27 | 31.82 | 23.65 |
| Cash ratio | 13.71 | 4.77 | 2.73 | 4.10 | 3.64 | 4.01 | 2.95 | 4.37 | 2.65 | 5.45 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.04 | 1.09 | 1.09 | 1.06 | 1.06 | 1.06 | 1.05 | 1.05 | 1.04 | 1.04 |
| Liabilities / Assets | 0.04 | 0.08 | 0.08 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.03 | 0.04 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.8x | - | 5.7x | 3.9x | 3.8x | - | 3.8x | 3.6x | 3.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -54.4% | - | -30.8% | -36.4% | -23.2% | - | -32.3% | -24.2% | -20.4% | - |
| Net income growth (YoY) | -57.3% | - | -44.8% | -46.2% | -35.7% | - | -29.6% | -22.0% | -14.9% | - |
| EPS growth (YoY) | -41.0% | - | -42.0% | -42.7% | -33.9% | - | -11.0% | -4.2% | -77.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -44.3% | - | - | - | -42.3% | - | - | - | -18.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 90.0% | -22.9% | -29.9% | -24.9% | -20.7% | -18.6% | 25.3% | 30.6% | 29.2% | 28.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Xenon Pharmaceuticals Inc. against the 5 most active filers in the same SIC group.